Russell Investments Group Ltd. Sells 302,245 Shares of 10x Genomics $TXG

Russell Investments Group Ltd. reduced its stake in 10x Genomics (NASDAQ:TXG – Free Report) by 53.6% during the third quarter, HoldingsChannel.com reports. The firm owned 262,062 shares of the company’s stock after selling 302,245 shares during the quarter. Russell Investments Group Ltd.’s holdings in 10x Genomics were worth $23,680,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Carolina Wealth Advisors LLC purchased a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $46,000. V Square Quantitative Management LLC purchased a new position in 10x Genomics during the third quarter valued at $68,000. Farther Finance Advisors LLC raised its stake in 10x Genomics by 29.9% during the third quarter. Farther Finance Advisors LLC now owns 934 shares of the company’s stock valued at $84,000 after buying an additional 215 shares during the last quarter. Elevation Wealth Partners LLC raised its stake in 10x Genomics by 332.3% during the second quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company’s stock valued at $57,000 after buying an additional 1,143 shares during the last quarter. Finally, CoreCap Advisors LLC boosted its holdings in 10x Genomics by 3,269.2% in the third quarter. CoreCap Advisors LLC now owns 1,752 shares of the company’s stock worth $158,000 after acquiring an additional 1,700 shares in the last quarter. 84.68% of the stock is owned by institutional investors.

10x Genomics Stock Up 2.4%

NASDAQ:TXG opened at $56.30 on Wednesday. The company’s 50 day moving average price is $73.58 and its 200-day moving average price is $42.91. 10x Genomics has a 52 week low of $15.18 and a 52 week high of $102.81. The stock has a market cap of $7.41 billion, a price-to-earnings ratio of -108.27 and a beta of 2.03.

10x Genomics (NASDAQ:TXG – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.12. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.19%. The company had revenue of $150.67 million during the quarter, compared to the consensus estimate of $147.96 million. During the same quarter last year, the firm earned ($0.22) earnings per share. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that 10x Genomics will post -0.67 earnings per share for the current year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 46,388 shares of the stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total transaction of $2,995,273.16. Following the sale, the chief financial officer directly owned 316,344 shares in the company, valued at approximately $20,426,332.08. This trade represents a 12.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Shehnaaz Suliman sold 5,723 shares of 10x Genomics stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total value of $464,650.37. Following the completion of the sale, the director directly owned 23,792 shares of the company’s stock, valued at approximately $1,931,672.48. The trade was a 19.39% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 190,333 shares of company stock worth $12,604,970. Insiders own 8.84% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Royal Bank Of Canada assumed coverage on 10x Genomics in a report on Tuesday, September 1st. They issued a “sector perform” rating and a $70.00 target price on the stock. Citigroup raised their price target on 10x Genomics from $50.00 to $60.00 and gave the company a “hold” rating in a report on Friday, November 6th. Stifel Nicolaus lifted their price target on 10x Genomics from $50.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Wall Street Zen raised 10x Genomics from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research note on Monday, September 21st. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of “Hold” and a consensus price target of $68.40.

View Our Latest Stock Report on TXG

About 10x Genomics

(Free Report)

10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.

Further Reading

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG – Free Report).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.